-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Upgrades Abbott Laboratories to Outperform, Announces $124 Price Target

Benzinga·11/19/2026 13:09:41
Listen to the news
Leerink Partners analyst Mike Kratky upgrades Abbott Laboratories (NYSE:ABT) from Market Perform to Outperform and announces $124 price target.